Neue Entwicklungen bei Nebennierenerkrankungen

Schlüsselwörter

Nebennierentumore - Inzidentalome - Nebenniereninsuffizienz

Keywords

adrenal tumors - incidentaloma - adrenal insufficiency

Literatur

• 1 Alkatib A A, Cosma M, Elamin M B, Erickson D, Swiglo B A, Erwin P J, Montori V M. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency.  J Clin Endocrinol Metab. 2009;  94 3676-3681
• 2 Barron J. Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis.  J Clin Pathol. 2010;  63 669-674
• 3 Betz M J, Degenhart C, Fischer E. et al . Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates.  Eur J Endocrinol. 2011;  165 301-306
• 4 Beuschlein F, Reincke M. [Every eighth case of hypertension originates in the adrenal gland. For whom is it worthwhile to screen for an endocrine cause?].  MMW Fortschr Med. 2010;  152 30-31
• 5 Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, Quinkler M. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.  Clin Endocrinol (Oxf). 2010;  72 297-304
• 6 Bornstein S R. Predisposing factors for adrenal insufficiency.  N Engl J Med. 2009;  360 2328-2339
• 7 Brix D, Allolio B, Fenske W. et al . Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.  Eur Urol. 2010;  58 609-615
• 8 Cawood T J, Hunt P J, O’Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?.  Eur J Endocrinol. 2009;  161 513-527
• 9 Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism.  J Clin Endocrinol Metab. 2011;  96 1223-1236
• 10 Comino-Mendez I, Gracia-Aznarez F J, Schiavi F. et al . Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.  Nat Genet. 2011;  43 663-667
• 11 de Bruin C, Feelders R A, Lamberts S W, Hofland L J. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome.  Rev Endocr Metab Disord. 2009;  10 91-102
• 12 Eisenhofer G, Lenders J W, Timmers H. et al . Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.  Clin Chem. 2011;  57 411-420
• 13 Fassnacht M, Johanssen S, Quinkler M. et al . Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.  Cancer. 2009;  115 243-250
• 14 Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update.  Nat Rev Endocrinol. 2011;  7 323-335
• 15 Fischer E, Beuschlein F, Reincke M. [Diagnosis of endocrinological hypertension: when to screen, and by which method?].  Dtsch Med Wochenschr. 2011;  136 537-540
• 16 Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism.  Rev Endocr Metab Disord. 2011;  12 43-48
• 17 Funder J W, Reincke M. Aldosterone: a cardiovascular risk factor?.  Biochim Biophys Acta. 2010;  1802 1188-1192
• 18 Johannsson G, Bergthorsdottir R, Nilsson A G, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet.  Eur J Endocrinol. 2009;  161 119-130
• 19 Krug A W, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?.  Hypertension. 2008;  51 1252-1258
• 20 Lovas K, Husebe E S. Continuous subcutaneous hydrocortisone infusion in Addison`s disease.  Eur J Endocrinol. 2007;  157 109-112
• 21 Nieman L K. Approach to the patient with an adrenal incidentaloma.  J Clin Endocrinol Metab. 2010;  95 4106-4113
• 22 Petrossians P, Thonnard A S, Beckers A. Medical treatment in Cushing’s syndrome: dopamine agonists and cabergoline.  Neuroendocrinology. 2010;  92 Suppl 1 116-119
• 23 Qin Y, Yao L, King E E. et al . Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.  Nat Genet. 2010;  42 229-233
• 24 Sbiera S, Schmull S, Assie G. et al . High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.  J Clin Endocrinol Metab. 2010;  95 (10) E161-71
• 25 Verma S, Vanryzin C, Sinaii N. et al . A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.  Clin Endocrinol (Oxf). 2010;  72 441-447